Dr. Peter P. Lacamera, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 338
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Massachusetts Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 160330 -
Critical Care Medicine (Internal Medicine) Physician
MA license 160330 -
Internal Medicine Physician
MA license 160330
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boston Medical Center Boston, MA
- Merrimack Health Lawrence Hospital Lawrence, MA
- Good Samaritan Medical Center Brockton, MA
- Boston Medical Center-Brighton Brighton, MA
Medical groups
- Bmc Affiliated Physicians, Inc. (564 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 338
- Services billed
- 732
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 248 | 178 |
| Critical care, first 30-74 minutes | 172 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 115 | 65 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 62 |
| New patient office or other outpatient visit, 45-59 minutes | 42 | 42 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| Administration of influenza virus vaccine | 17 | 17 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 16 | 16 |
| Established patient office or other outpatient visit, 40-54 minutes | 12 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boston, MA | 387 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boston, MA | 271 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Boston, MA | 101 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Boston, MA | 87 |
| Prednisone Other prescribers in Boston, MA | 77 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in Boston, MA | 64 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Boston, MA | 63 |
| Ofev (nintedanib esylate) | 58 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Boston, MA | 48 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Boston, MA | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $223,121 in research payments for these studies, mostly to the institutions running them.
- An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Boehringer Ingelheim Pharmaceuticals, Inc. - A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Boehringer Ingelheim Pharmaceuticals, Inc. - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON)
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in PF-ILD
Boehringer Ingelheim International GmbH - PDE4 Phase III trial in IPF patients
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.